Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of ECC5004 in Healthy Participants and Type 2 Diabetes Patients
NCT05654831Phase 1Completed
- Sponsor
- Eccogene
- Start
- Dec 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of elecoglipron in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Eccogene. Primary endpoint: Number of participants with adverse events, with abnormal laboratory test results, abnormal ECGs, abnormal vital signs, and abnormal physical examinations. Started Dec 2022; status: completed.
02
Drugs
elecoglipron
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05654831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05654831.